Aleksander B. Skotnicki

Author

Also Known As

A B Skotnicki, Aleksander B Skotnicki, Aleksander B. Skotnicki, Aleksander Bartlomiej Skotnicki, Aleksander Bartłomiej Skotnicki, Aleksander SKOTNICKI, Aleksander Skotnicki, Aleksander Skotñicki, Aleksander B. Skotnicki, Philippe de Moerloose

244

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

Jagiellonian University Wroclaw Medical University Gdańsk Medical University Medical University of Silesia Medical University of Warsaw

About

Aleksander B. Skotnicki is an author at Jagiellonian University specializing in medicine, hematology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	18	759
2	Health Sciences	5	5	448
3	Cell Biology	2	2	44
4	Public Health	1	1	11
5	Blood Transplantation	1	1	58

Aleksander B. Skotnicki

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia Peter Hillmen, Aleksander B. Skotnicki, Tadeusz Robak, Journal of Clinical Oncology	2007	555
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial Hagop Kantarjian, Ricardo Pasqüini, Nelson Hamerschlak, Blood	2007	377
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study Heinz Gisslinger, Christoph Klade, Pencho Georgiev, The Lancet Haematology Polycythaemia VeraHematologyClinical TrialsTranslational ResearchExtension Study	2020	327
Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Susan O’Brien, Joseph O. Moore, Thomas E. Boyd, Journal of Clinical Oncology	2007	298
Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study Jerzy Hołowiecki, Sebastian Grosicki, Sebastian Giebel, Journal of Clinical Oncology	2012	258
Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Tadeusz Robak, Marek Kasznicki, Maria Błasińska-Morawiec, PubMed	2000	221
5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Susan O’Brien, Joseph O. Moore, Thomas E. Boyd, Journal of Clinical Oncology	2009	163
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G‐CSF (CLAG‐M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group Agnieszka Wierzbowska, Tadeusz Robak, Agnieszka Pluta, European Journal Of Haematology	2007	142
Status of minimal residual disease after induction predicts outcome in both standard and high‐risk Ph‐negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4‐2002 MRD Study Jerzy Hołowiecki, Małgorzata Krawczyk‐Kuliś, Sebastian Giebel, British Journal of Haematology	2008	142
Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A Johnny Mahlangu, Kazimierz Kuliczkowski, Faraizah Abdul Karim, Blood	2016	85

Page 1